phase 1
ii 1
randomized 1
trial 2
comparing 1
standard 1
low 1
dose 1
rituximab 1
combined 1
alemtuzumab 1
initial 1
treatment 1
progressive 1
chronic 1
lymphocytic 1
leukemia 1
older 1
patients 1
ecogacrin 1
cancer 1
research 1
group 1
e 1
association 1
between 1
early 2
life 2
adult 1
body 1
mass 1
index 1
physical 1
activity 1
risk 3
nonhodgkin 2
lymphoma 3
impact 1
gender 1
sun 1
exposure 1
vitamin 1
drelated 1
gene 1
variants 1
germline 1
variation 1
apoptosis 1
pathway 1
genes 1
nonhodgkins 1
